Edwards Lifesciences Corp.’s Sapien transcatheter aortic heart valve has a two-year mortality rate that matches that of open surgical valve replacement, recent data show. And a leading trial investigator suggests the findings offer a possible path to meaningfully reducing, rather than simply matching, mortality rates versus surgery.
Clinicians reported two-year data from the high-surgical-risk cohort of Edwards’ PARTNER trial March 26 at the American College of Cardiology annual meeting in Chicago